Bortezomib (a proteasome inhibitor) has recently been approved for treatment of relapsed multiple myeloma, a plasma cell neoplasia, owing to the sensitivity of immunoglobulin-synthesizing myeloma ...

A common reason for these failures is limited information about a new drug’s mechanism of action (MoA). To reduce the ... those of known drugs identified bortezomib, approved for the treatment ...